Madal prealbumiinisisaldus ei tõenda alatoitumust: põletik, maksafunktsioon, neerufunktsioon ja vedelikutasakaal võivad tulemust toidutarbimisest sõltumatult muuta. Tulemuse kasulik tõlgendamine seostab näidu kehakaalu muutuste, lihasmassi vähenemise, tegeliku toidutarbimise ja analüüsi põhjuseks oleva haigusega.
Peamised järeldused
- Madal prealbumiinisisaldus tähendab, et selle valgu kontsentratsioon veres on teie labori referentsvahemikust väiksem; tulemus 12 mg/dL ei tõenda alatoitumust.
- Prealbumiini normaalvahemik on täiskasvanutel tavaliselt ligikaudu 20–40 mg/dL ehk 0,20–0,40 g/L, kuid laborid kasutavad erinevaid referentsvahemikke.
- Põletik võib vähendada prealbumiini tootmist hoolimata piisavast söömisest; selle ligikaudu 2–3-päevase poolväärtusaja tõttu ilmnevad haigusega seotud muutused kiiresti.
- CRP kontekst aitab selgitada madalat prealbumiinisisaldust, kuid valideeritud CRP korrigeerimise valemit, mis teisendaks tulemuse toitumuslikuks seisundiks, ei ole.
- Alatoitumuse diagnoos GLIM-i järgi eeldab pärast toitumisriski sõeluuringut vähemalt 1 fenotüübilise ja 1 etioloogilise kriteeriumi täitmist — üksnes madal valgusisaldus ei ole piisav.
- Kaalulangus üle 5% 6 kuu jooksul on GLIM-i fenotüübiline kriteerium, isegi kui KMI jääb tavapärasest tervisliku kehakaalu vahemikust kõrgemaks.
- Toitumisalane tugi peaks vastama dokumenteeritud vajadustele ja söömisega seotud takistustele; NICE-i üldised hinnangud 25–35 kcal/kg/päevas ei sobi kõigile alustamise sihtväärtusteks.
- Toitmise taasalustamise risk vajab kliinilist hindamist pärast pikaajalist minimaalset toidu tarbimist; üle 10 päeva vähese või olematu toitainete saamisega on üks NICE-i suure riski kriteeriume.
Kas madal prealbumiinisisaldus tähendab, et olete alatoitunud?
Madal prealbumiin võib kaasneda alatoitumusega, kuid selle põhjal ei saa alatoitumust diagnoosida. Kontsentratsioon 12 mg/dL võib viidata põletikule, maksas sünteesi häirumisele, ebapiisavale toidu tarbimisele või mitme teguri koosmõjule; toitumusseisundi hindamiseks tuleb hinnata kehakaalu, lihasmassi, toidu tarbimist ja põhihaigust.
Laboratoorne märge kirjeldab ühe valgu kontsentratsiooni, mitte lihastesse talletatud valgu hulka. 2021. aasta ASPEN-i seisukohadokumendis öeldakse, et albumiin ja prealbumiin iseloomustavad eeskätt põletikku, mitte toitumusseisundit, ning neid ei tohiks kasutada keha valgusisalduse või lihasmassi asendusnäitajatena (Evans jt, 2021). Madalad väärtused võivad siiski osutada inimestele, kes vajavad hoolikamat kliinilist jälgimist.
Mõelge hüpoteetilisele täiskasvanule, kes sööb nagu tavaliselt, kuid haigestub kopsupõletikku ja kelle prealbumiinisisaldus on 11 mg/dL. Teine täiskasvanu, kelle tulemus on sama, võib olla söönud 3 nädalat väga vähe, sest neelamine on raske; identne arv ei ütle arstidele, kumb selgitus kehtib. Mõlemad vajavad hindamist, kuid ravi prioriteedid on erinevad.
Kantesti on tehisintellektil põhinev vereanalüüside analüsaator, mis aitab selgitada, miks prealbumiini tulemus 12 mg/dL vajab kliinilist konteksti, mitte automaatset alatoitumuse märgistust. Meie organisatsioon ja eesmärk eesmärk on muuta laboriteave arusaadavaks, mitte asendada arsti läbivaatust või toitumisnõustaja hinnangut. Oluline küsimus on, mis tulemust selgitab ja millised tõendid kinnitavad toitumisprobleemi sõltumatult.
Milline on prealbumiini normaalvahemik?
Täiskasvanute puhul kasutatakse sageli prealbumiini normaalvahemikku ligikaudu 20–40 mg/dL, mis vastab 0,20–0,40 g/L. Esmatähtis on teie analüüsivastusel esitatud vahemik, sest piire mõjutavad vanus, analüüsimeetod ja labori võrdluspopulatsioon.
Erinevad võrdlusvahemikud ei tähenda tingimata, et üks labor on eksinud. Mõnes vastuses kasutatakse vahemikke ligikaudu 15–36 mg/dL, seega võidakse hüpoteetiline väärtus 18 mg/dL ühes laboris märkida normist kõrvalekalduvaks ja teises mitte; kumbki liigitus ei kinnita eraldi võetuna toitumise piisavust. Võrdlusvahemikud kirjeldavad võrdluspopulatsiooni, diagnostilised kriteeriumid peavad aga tuvastama kliiniliselt olulise seisundi.
Ühikute teisendamine võib ära hoida palju suurema arusaamatuse kui piiripealne märge. Prealbumiini sisaldus 200 mg/L võrdub 20 mg/dL ja 0,20 g/L; seega tähendab analüüsivastusel esitatud 0,18 g/L 18 mg/dL, mitte erakordselt väikest kontsentratsiooni. Enne kahe analüüsivastuse võrdlemist kontrollige ühikuid, labori vahemikku ja proovivõtu asjaolusid, mitte üksnes võrrelge esitatud arve.
Kontsentratsioon alla 10 mg/dL jääb paljudest täiskasvanute võrdlusvahemikest oluliselt allapoole, kuid puudub universaalne üksnes prealbumiinil põhinev erakorralise sekkumise piirväärtus või alatoitumuse raskusastme valideeritud skaala. albumiini ja seerumi valkude juhend selgitab, miks vereringes olevaid valke ei saa samastada toitumisseisundi hindamisega. Laste tulemusi tuleb tõlgendada vanusepõhiselt; allolevat täiskasvanute tabelit ei tohiks lastele kohaldada.
| Tase | Vahemik | Mida see tähendab |
|---|---|---|
| Tavapärane täiskasvanute vahemik | 20–40 mg/dL | Ühe tavapäraselt kasutatava vahemiku piires; ei välista alatoitumust. |
| Sellest näidisvahemikust madalam | 10–<20 mg/dL | Review inflammation, intake, liver function, kidney function, and fluid balance. |
| Markedly below this interval | <10 mg/dl | Needs clinical explanation; not a stand-alone malnutrition grade or emergency cutoff. |
| Above this example interval | >40 mg/dL | May occur with reduced renal catabolism or medication effects; does not prove excellent nutrition. |
Mida prealbumiini analüüs tegelikult mõõdab?
The prealbumin test measures transtüretiiniks, a transport protein produced mainly by the liver for circulation. Its approximately 2–3-day half-life allows relatively rapid changes, but a rapid response does not make it specific to food intake.
Prealbumin is not an immature form of albumin and does not turn into albumin. The name comes from its migration ahead of albumin during electrophoresis; albumin has a much longer circulating half-life, roughly 20 days, compared with about 2–3 days for prealbumin. These different turnover rates explain why the two results can move at different speeds during an illness.
Transthyretin normally forms a tetramer of 4 protein subunits and carries some circulating thyroxine, or T4. It also interacts with retinol-binding protein, which carries vitamin A; a low prealbumin concentration nevertheless does not independently diagnose either thyroid disease or vitamin A deficiency. Transport-protein concentration, hormone activity, and tissue nutrient stores answer different biological questions.
A low concentration is also different from finding a disease-associated variant in the TTR gene. A hypothetical prealbumin result of 14 mg/dL is not a genetic screening result and does not diagnose hereditary ATTR amyloidosis; that evaluation uses a separate clinical and genetic pathway. Our explanation of TTR variants and amyloidosis helps separate these easily confused meanings of the same protein name.
Miks põletik vähendab prealbumiinisisaldust ka söömise korral?
Prealbumin is a negative acute-phase protein: its circulating concentration often falls during inflammation as liver protein production changes. A hypothetical value of 10 mg/dL during severe illness can therefore occur even when recent calorie and protein intake have been adequate.
Inflammatory signaling changes what the liver produces rather than simply indicating that the patient skipped meals. Mediators including interleukin-6 promote the acute-phase response, while concentrations of proteins such as prealbumin can decline; its 2–3-day half-life makes that shift relatively quick. The IL-6 interpretation guide explains why timing and illness context matter, although IL-6 testing is not routinely needed to assess nutrition.
Inflammation can lower prealbumin independently of intake and also increase nutritional risk through appetite loss and catabolism. These are 2 overlapping processes, not competing explanations: a person may initially eat adequately yet lose muscle during prolonged illness because the body's metabolic demands and tissue breakdown have changed. Calling the result 'just inflammation' can therefore be as misleading as calling it proof of starvation.
Other negative acute-phase proteins may move in the same direction, so a combination of low prealbumin and low transferrin does not provide 2 independent confirmations of malnutrition. Their shared response to inflammation can create an apparently convincing pattern from the same underlying mechanism. Our guide to inflammation and low transferrin explains why clinicians examine the cause before interpreting several low transport proteins as dietary deficiencies.
Kuidas tuleks prealbumiini ja CRP-d koos tõlgendada?
CRP helps identify inflammatory context, but it cannot correct prealbumin into a nutrition score. A hypothetical combination of prealbumin 12 mg/dL and CRP 90 mg/L strongly raises concern that an acute-phase response is influencing the protein result.
A normal CRP reduces evidence for a substantial systemic acute-phase response at that moment, but it does not prove that low prealbumin is dietary. Many laboratories use a CRP upper limit around 5 mg/L, while others use 10 mg/L; sampling timing, localized disease, and liver disease can complicate interpretation. There is no universal CRP cutoff below which prealbumin becomes a validated malnutrition test.
Discordant inflammatory markers should lead to questions about timing, symptoms, and treatment rather than a mathematical workaround. A hypothetical patient with prealbumin 13 mg/dL, CRP 4 mg/L, and a normal white cell count still needs an intake and weight history; clinicians may also investigate liver function or persistent symptoms. Our discussion of disagreeing infection markers explains why one reassuring marker cannot settle the whole clinical picture.
Kantesti AI can help readers distinguish a prealbumin result of 12 mg/dL from a CRP result of 90 mg/L and understand what each measurement contributes. Neither a prealbumin-to-CRP ratio nor dividing one value by the other is an accepted substitute for nutritional assessment. When CRP is missing, that uncertainty should remain visible—not be replaced by a confident dietary diagnosis.
Kuidas muudavad maksa- ja neeruhaigused prealbumiinisisaldust?
Liver disease can reduce prealbumin production, while impaired kidney function can increase its concentration through reduced catabolism. A value of 15 mg/dL or 45 mg/dL therefore cannot be interpreted as poor or excellent nutrition without knowing the organ-function context.
Reduced hepatic synthetic capacity is different from an isolated rise in a liver enzyme. A hypothetical ALT of 80 IU/L does not quantify how much prealbumin the liver can produce; clinicians consider the broader pattern, including albumin, bilirubin, coagulation results, history, and examination. The tsirroosi laboratoorsed vihjed guide explains why apparently modest enzyme changes can coexist with more significant liver dysfunction.
Kidney disease can pull the result in more than one direction because reduced catabolism may raise prealbumin while concurrent inflammation or poor intake lowers it. A hypothetical adult with eGFR 25 mL/min/1.73 m² and prealbumin 38 mg/dL may still have clinically significant weight and muscle loss. Our guide to madala eGFR hoiatusmärgid explains the kidney findings that deserve attention beyond this transport protein.
Protein loss in urine should be assessed directly rather than inferred from prealbumin. Urine albumin or protein measurements, serum albumin, and kidney evaluation answer questions that a prealbumin concentration of 16 mg/dL cannot resolve; nephrotic conditions do not produce a reliably predictable prealbumin pattern. The practical step is to bring renal results and liver results to the same appointment, especially before changing protein intake substantially.
Kas vedelikud, ravimid või analüüsimeetodi probleemid võivad tulemusi muuta?
Fluid balance, some medicines, and method-specific assay interference can change prealbumin test results. A hypothetical decline from 22 to 16 mg/dL after major fluid administration may partly reflect dilution rather than a sudden change in nutritional reserves.
Prealbumin is a concentration measurement, so the amount of circulating fluid affects how the result is expressed. Rapid fluid retention can lower measured concentrations, while dehydration can raise them; a 3 kg weight increase over several days may represent fluid rather than new tissue. Clinicians therefore distinguish weight recovery from edema and avoid interpreting a falling protein concentration in isolation after resuscitation.
Corticosteroids can increase prealbumin concentrations, although the overall result also depends on the illness being treated. A hypothetical change from 18 to 25 mg/dL after corticosteroid treatment could reflect medication effects, reduced inflammation, nutritional changes, or a mixture of all 3. Record the medicine's name, dose, and start date rather than assuming every increase means that a nutrition plan succeeded.
An unexpected isolated result deserves a check of units, specimen quality, and the laboratory's interference notes before extensive dietary changes. A hypothetical prealbumin of 9 mg/dL alongside several unexpected assay findings may justify discussion with the laboratory; interference is method-dependent, not something every patient needs repeat testing for. Our explanation of inflammation and plasma zinc also shows why several low circulating nutrients or proteins may share a non-dietary explanation.
Milliste kriteeriumide alusel diagnoositakse täiskasvanutel alatoitumust?
GLIM diagnoses adult malnutrition using at least 1 phenotypic criterion and 1 etiologic criterion after nutritional risk screening. Phenotypic criteria include weight loss, low BMI, or reduced muscle mass; etiologic criteria include reduced intake or assimilation, or inflammation and disease burden.
The international GLIM consensus uses unintentional weight loss greater than 5% within 6 months, or greater than 10% beyond 6 months, as a phenotypic criterion (Cederholm et al., 2019). A hypothetical change from 70 to 66 kg is approximately 5.7% loss, even if the person still appears well nourished. The timing and whether the loss was intended matter as much as the arithmetic.
GLIM's commonly used non-Asian low-BMI thresholds are below 20 kg/m² for adults younger than 70 and below 22 kg/m² for adults aged 70 or older, with population-specific adaptations. These are diagnostic-framework thresholds, not universal healthy-weight boundaries; reduced muscle mass can establish a phenotype even when BMI is higher. Neither BMI nor prealbumin alone captures how much functional tissue a person has lost.
Kantesti is an AI biomarker interpretation platform that explains why prealbumin of 14 mg/dL cannot replace GLIM's clinical criteria. Specific deficiencies can coexist with malnutrition, but a low folate result is a different diagnostic question from total calorie and protein adequacy; our guide to folate deficiency causes makes that distinction. A nutrition assessment should identify the syndrome and its cause, not collect abnormal laboratory flags as a substitute.
Mida peaks põhjalik toitumuse hindamine hõlmama?
A useful nutrition assessment documents weight trajectory, actual intake, eating barriers, muscle changes, and disease burden. Reviewing the previous 1–6 months often reveals more than a single prealbumin concentration, particularly when fluid retention or a higher BMI hides tissue loss.
A higher BMI does not exclude malnutrition after substantial unintentional weight loss. A hypothetical adult weighing 80 kg who falls to 74 kg has lost 7.5%; at 1.65 m tall, the current BMI remains approximately 27.2 kg/m² despite that meaningful change. Clinicians ask whether clothing fits differently, strength has declined, and swelling is masking further tissue loss rather than judging nutritional status from appearance.
Reduced intake should be investigated as a symptom with a cause, not treated as a failure of motivation. Difficulty swallowing, painful eating, nausea, dental problems, limited food access, and medication effects require different solutions; a 3-day food record can help describe the pattern but does not diagnose malabsorption. Persistent swallowing problems may need evaluation such as the pathway described in our achalasia diagnostic guide.
Digestive investigations should follow symptoms and risk factors instead of being ordered because prealbumin is below 20 mg/dL. Chronic diarrhea with weight loss may warrant targeted evaluation for intestinal disease, whereas visible food fragments alone do not establish nutrient malabsorption. Our guide to stool inflammation tests explains what those tests can contribute; muscle assessment and intake history still remain necessary even when gastrointestinal testing identifies a cause.
Millal on prealbumiini kordusanalüüs tegelikult kasulik?
Repeating prealbumin is useful only when the result will answer a defined clinical question. Its 2–3-day half-life does not justify routine testing every few days, and an increase cannot independently prove that nutrition treatment has restored muscle or body protein.
Prealbumin can rise as inflammation resolves even when food intake has changed very little. In a hypothetical recovery, prealbumin increases from 10 to 18 mg/dL while CRP falls from 120 to 8 mg/L over 10 days; the pattern supports a changing acute-phase response but cannot quantify how much nutrition contributed. Improved concentration is not equivalent to restored strength, healed tissue, or replenished lean mass.
If a clinician chooses to repeat testing, an interval such as 1–2 weeks after a meaningful clinical change may be reasonable, but it is not a universal guideline schedule. Record the illness course, fluid status, medication changes, intake, and laboratory method at both time points. Our guide to meaningful laboratory trends explains why the circumstances surrounding each measurement determine whether comparison is informative.
Kantesti can help organize dated prealbumin measurements, but 2 results cannot reveal unrecorded food intake or establish muscle recovery. ASPEN's 2021 position paper advises against using visceral proteins as nutrition markers, so clinical outcomes and documented intake should lead monitoring rather than a target prealbumin value (Evans et al., 2021). Ask what management decision would change before arranging another measurement.
Kas prealbumiinisisalduse suurendamiseks peaks valgutarbimist suurendama?
Increase nutrition when an assessment identifies inadequate intake or increased needs—not simply to push prealbumin above 20 mg/dL. A low result does not specify a protein dose, and kidney disease, severe illness, fluid restrictions, and refeeding risk can change the appropriate plan.
For adults requiring nutrition support who are not severely ill and are not at refeeding risk, NICE CG32 gives general estimates of 25–35 kcal/kg/day and 0.8–1.5 g protein/kg/day (NICE, 2006). These are planning ranges with clinical exceptions, not instructions for everyone with low prealbumin. The CG32 nutrition-support guidance also addresses fluid, electrolytes, micronutrients, and the route through which nutrition is delivered.
A hypothetical 60 kg adult would have an estimated range of 1,500–2,100 kcal/day and 48–90 g protein/day under those general assumptions. The wide range reflects different needs; it is not a reason to choose the highest protein intake automatically, particularly with kidney disease. Our discussion of neerudieedi ohutud piirnormid explains why an AI-generated plan still needs appropriate clinical constraints.
Food fortification or oral nutrition supplements may help when ordinary meals do not meet documented needs, but treating the eating barrier remains necessary. A hypothetical person managing only 50% of meals because of persistent nausea needs evaluation of the nausea as well as a feasible nutrition plan. There is no established prealbumin threshold that automatically requires protein powders, intravenous nutrition, or a particular supplement formulation.
Millal vajavad vähene toidutarbimine ja haigus kiiret tähelepanu?
Urgency comes from symptoms, prolonged inadequate intake, and metabolic risk—not the prealbumin number alone. NICE identifies more than 10 days with little or no nutrition as one high-risk criterion for refeeding problems, which require supervised nutrition restoration.
Seek urgent care for confusion, fainting, severe weakness, inability to keep fluids down, very little urine, or breathing difficulty, regardless of whether prealbumin is 8 or 28 mg/dL. Persistent vomiting or diarrhea can create dehydration and electrolyte problems before a transport-protein result becomes informative. Our digestive warning signs guide helps distinguish symptoms that need assessment rather than another nutrition-marker test.
Refeeding risk depends on history and clinical findings, not on a low prealbumin concentration. NICE lists BMI below 16 kg/m², unintentional weight loss greater than 15% over 3–6 months, more than 10 days of minimal intake, or low potassium, phosphate, or magnesium before feeding as individual high-risk criteria; combinations of less severe findings can also qualify. A normal initial electrolyte result does not guarantee that body stores are adequate.
For people who have eaten little or nothing for more than 5 days, NICE recommends initially introducing nutrition at no more than 50% of requirements for the first 2 days, with monitoring. High-risk plans may start at no more than 10 kcal/kg/day under experienced clinical supervision, with thiamine and electrolyte management (NICE, 2006). These figures explain why simply drinking several high-calorie supplements at once can be unsafe after prolonged restriction—they are not a home treatment protocol.
Kuidas saab AI aidata prealbumiinisisaldust ohutult tõlgendada?
AI can explain prealbumin terminology, organize related results, and identify missing context; it cannot diagnose nutritional status from a laboratory report alone. A result of 12 mg/dL needs information about illness, intake, weight, medications, and organ function before its meaning becomes clearer.
Kantesti is an AI blood test interpretation platform that helps explain why prealbumin of 12 mg/dL and CRP of 90 mg/L should be read as different measurements. Our AI tehnoloogia selgitus describes the interpretation workflow; the safe clinical boundary remains the same whether the explanation is generated quickly or reviewed slowly. Software cannot palpate muscle, observe swallowing, or independently verify the meals someone actually consumed.
A useful interpretation separates measured facts from missing information instead of presenting one confident diagnosis. For example, a hypothetical report containing prealbumin 12 mg/dL but no CRP or weight history should describe those gaps and suggest discussion of nutritional screening, rather than assign a malnutrition grade. Check whether the explanation preserves your laboratory's units and reference interval before using it to prepare questions for an appointment.
Clinical standards should be judged against the specific task, not a broad accuracy claim that covers every medical decision. Even a correct interpretation of 20 mg/dL cannot establish nutrition adequacy without an assessment, and no software benchmark changes that limitation. Our valideerimis- ja järelevalveraamistik is relevant to evaluating methodology; decisions about nutrition support, diagnosis, or urgent care remain matters for qualified healthcare professionals.
Millised publikatsioonid toetavad neid toitumisega seotud piiranguid?
The clinical conclusions here rest on nutrition guidance, not on unrelated AI publications. The 2021 ASPEN position paper, the 2019 GLIM consensus, and NICE CG32 address different questions: protein-marker limitations, malnutrition diagnosis, and safe nutrition support.
ASPEN's 2021 paper explains why low visceral proteins should not serve as nutrition markers, while GLIM's 2019 consensus specifies the clinical criteria needed to diagnose malnutrition. Neither establishes a prealbumin-only diagnostic cutoff such as 10 or 15 mg/dL; these numbers can describe laboratory abnormalities without proving their cause. NICE CG32 adds practical safety guidance for nutrition support, including the separate assessment of refeeding risk.
Shared inflammatory effects also explain why a broader laboratory panel needs careful interpretation rather than simple abnormal-result counting. A hypothetical low prealbumin of 13 mg/dL alongside low transferrin may reflect one acute-phase mechanism; ferritin can move in the opposite direction during inflammation and complicate assessment of iron stores. Our rauauuringute tõlgendusjuhendit explains why biochemical pattern recognition must remain connected to the clinical question.
Kantesti's 2 Figshare publications listed below concern women's health education and multilingual hantavirus decision support, respectively. They are included as separate research resources, not as evidence that prealbumin diagnoses malnutrition or that an AI nutrition plan improves clinical outcomes. Our meditsiinilise sisu standardid explain the source-quality distinction readers should expect: a repository DOI identifies a publication, but it does not by itself establish peer review or relevance to this nutrition question.
Korduma kippuvad küsimused
Kas madal prealbumiin tähendab alati alatoitumust?
Madal prealbumiinisisaldus ei tähenda alati alatoitumust ning ainuüksi selle põhjal ei saa seda diagnoosida. Tulemus 12 mg/dL võib viidata põletikule, vähenenud tootmisele maksas, ebapiisavale toidu tarbimisele või mitme põhjuse koosmõjule. Täiskasvanute alatoitumuse hindamisel võetakse arvesse tahtmatut kaalulangust, lihasmassi, toidu tarbimist või omastamist ning haiguse raskust. GLIM-i raamistik nõuab pärast toitumisriski sõeluuringut vähemalt 1 fenotüübilise ja 1 etioloogilise kriteeriumi täitmist.
Milline on normaalne prealbumiini tase?
Täiskasvanutel tavaliselt kasutatav prealbumiini referentsvahemik on ligikaudu 20–40 mg/dL ehk 0.20–0.40 g/L. Mõned laborid kasutavad teistsuguseid vahemikke, seega lähtuge oma analüüsivastusele märgitud vahemikust. Väärtus 200 mg/L võrdub 20 mg/dL-ga, mis on oluline erinevaid ühikuid kasutavate analüüsivastuste võrdlemisel. Vahemikku jääv tulemus ei välista alatoitumust ning laste tulemusi tuleb tõlgendada vanuse alusel.
Kas põletik võib prealbumiini taset langetada, kui ma söön piisavalt?
Põletik võib prealbumiini taset langetada isegi siis, kui hiljutine toidutarbimine on olnud piisav, sest prealbumiin on negatiivne ägeda faasi valk. Selle ligikaudu 2–3-päevane poolväärtusaeg võimaldab kontsentratsioonil suhteliselt kiiresti muutuda, kui valkude tootmine maksas haiguse ajal muutub. CRP võib aidata seda olukorda tuvastada, kuid toitumusseisundi hindamiseks ei ole valideeritud CRP korrigeerimisvalemit. Piisav söömine ei hoia ära ka haigusega seotud lihaskadu pikaajalise katabolismi korral.
Kas prealbumiini tase alla 10 mg/dl on ohtlik?
Prealbumiini alla 10 mg/dl jääb märkimisväärselt allapoole paljusid täiskasvanute võrdlusvahemikke, kuid see ei ole iseseisev erakorralise abi lävend ega valideeritud alatoitumuse raskusastme näitaja. Kiireloomulisuse hindamiseks võtavad arstid arvesse põhihaigust, toidu tarbimist, kehakaalu muutust, elundite talitlust ja sümptomeid. Segasus, minestamine, võimetus vedelikke sees hoida, väga vähene uriinieritus või hingamisraskus vajavad kiiret hindamist prealbumiini tulemusest olenemata. Enne toitumise kiiret suurendamist tuleb hinnata ka pikaajalise minimaalse toidutarbimisega kaasnevat toitmise taasalustamise sündroomi riski.
Kui kiiresti peaks prealbumiini tase parema toitumise korral paranema?
Puudub usaldusväärne prealbumiini paranemise ajakava, mis tõendaks, et toitumisravi toimib. Kuigi selle poolväärtusaeg on ligikaudu 2–3 päeva, võib prealbumiinitase tõusta põletiku taandumise või ravimite ja vedelikutasakaalu muutumise tõttu. Seetõttu ei saa oletatav tõus 10-lt 18 mg/dL-ni üksi toitumusliku taastumise ulatust näidata. Jälgimisel tuleks keskenduda dokumenteeritud toidutarbimisele, kehakaalule vedelikutasakaalu arvesse võttes, lihaste funktsioonile ja põhihaiguse kliinilisele kulule.
Kas peaksin madala prealbumiinisisalduse korral võtma valgulisandeid?
Madal prealbumiinitulemus üksi ei näita, et valgulisandid oleksid vajalikud, ega määra kindlaks ohutut annust. Valitud täiskasvanutele, kes vajavad toitmisravi, kuid kellel ei ole rasket haigust ega toitmise taasalustamisega seotud riski, annab NICE üldiseks planeerimisaluseks 0,8–1,5 g valku/kg päevas; individuaalne vajadus ja piirangud on siiski erinevad. Neeruhaigus, neelamisprobleemid ja pikaajaline väga vähene söömine võivad sobivat plaani muuta. Püüdke laborinäitu tõsta üritamise asemel rääkida tegelikust toidukogusest ja toitumusriskist tervishoiutöötaja või dietoloogiga.
Saage teada, kuidas lugeda vereanalüüsi tulemusi
Laadige oma laboriaruanne üles ja Kantesti AI selgitab iga biomarkerit sekunditega lihtsas keeles. Kasutusel enam kui 2 miljoni inimese seas kogu maailmas.
Viited
- Klein, T., Mitchell, S., & Weber, H. (2026). Naiste tervise juhend: ovulatsioon, menopaus ja hormonaalsed sümptomid. Kantesti AI meditsiiniuuringud. DOI
- Klein, T., Mitchell, S., & Weber, H. (2026). Mitmekeelne tehisintellektipõhine kliiniline otsustustugi hantaviiruse varaseks triaažiks: kavandamine, tehniline valideerimine ja rakendamine tegelikes oludes 50 000 tõlgendatud vereanalüüsi vastuse põhjal. Kantesti AI meditsiiniuuringud. DOI
- Evans DC et al. (2021). The Use of Visceral Proteins as Nutrition Markers: An ASPEN Position Paper. Nutrition in Clinical Practice. DOI
- Cederholm T et al. (2019). GLIM criteria for the diagnosis of malnutrition – A consensus report from the global clinical nutrition community. Clinical Nutrition. DOI
- National Institute for Health and Care Excellence (2006). Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition. NICE Clinical Guideline CG32.
- 2+ kuudAnalüüsitud testid
- 127+Riigid
- 100+Keeled
Meditsiinimeeskonnast
E-E-A-T usaldussignaalid
Kogemus
Arsti juhitud kliiniline ülevaade labori tõlgendamise töövoogudest.
Ekspertiis
Laborimeditsiin keskendub sellele, kuidas biomarkerid käituvad kliinilises kontekstis.
Autoriteetsus
Meditsiiniliselt retsenseerinud dr Thomas Klein, kaastöölised dr Sarah Mitchell ja prof dr Hans Weber.
Usaldusväärsus
Tõenduspõhine tõlgendus selgete edasiste sammudega, et vähendada ärevust.
Meditsiiniline lahtiütlus
Käesolev artikkel on mõeldud üksnes hariduslikel eesmärkidel ega kujuta endast meditsiinilist nõuannet. Diagnoosi ja ravivalikute otsuste tegemiseks konsulteeri alati kvalifitseeritud tervishoiutöötajaga.
Avaldatud · Võtke ühendust toimetusega
Avaldanud Kantesti Ltd, registreeritud Inglismaal ja Walesis, ettevõtte nr. 17090423, London, Ühendkuningriik.
